Clinical Trial Search

Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants

Primary: Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review — 0; 34 Percentage of participants — p=0.0012

Primary: Number of Participants With Adverse Events (AEs) — 60 Participants

Primary: Objective Response Rate — 2; 4; 6; 17 Participants

Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 5040.638; 454.392 picogram/milliliter (pg/mL)

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg

Primary: Number of Participants With Toxicity — 8 participants

Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants

Primary: Rate of Immunological Response to Vaccination — 0; 15 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants

Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator — 30…

Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants

Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants

Primary: Response Rate — 0; 0; 1; 1 Participants

Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Progression Free Survival (PFS) — 6.6 months

Primary: Number of Participants With a Response to Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With…

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: ORR — 88; 81 percentage of patients

Primary: Objective Response Rate — .85 proportion of patients